HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial.

AbstractPURPOSE:
A randomized clinical trial from Great Britain suggested a possible beneficial effect of acetylsalicylate in the prevention of radiation-induced bowel toxicity. Olsalazine is an orally administered drug designed to deliver 5-aminosalicylate to the large bowel with minimal systemic absorption. A randomized clinical trial was undertaken to assess the effectiveness of olsalazine in preventing acute diarrhea in patients receiving pelvic radiation therapy.
METHODS AND MATERIALS:
Patients receiving pelvic radiation therapy were randomized, in double-blind fashion, to olsalazine 250 mg, two capsules twice daily, or an identical appearing placebo, two capsules twice daily. Patients were then evaluated weekly during radiation therapy for the primary study endpoint, diarrhea, as well as rectal bleeding, abdominal cramping, and tenesmus.
RESULTS:
The study was closed early, after entry of 58 evaluable patients, when a preliminary analysis showed excessive diarrhea in patients randomized to olsalazine. The incidence and severity of diarrhea were worse in patients randomized to olsalazine (p = 0.0036). Sixty percent of the patients randomized to olsalazine experienced Grade 3 or 4 diarrhea compared to only 14% randomized to placebo. There was also a trend toward higher incidence and greater severity of abdominal cramping in patients who were randomized to olsalazine (p = 0.084).
CONCLUSION:
Administration of olsalazine during pelvic radiation therapy resulted in an increased incidence and severity of diarrhea. Olsalazine is contraindicated in patients receiving pelvic radiation therapy.
AuthorsJ A Martenson Jr, G Hyland, C G Moertel, J A Mailliard, J R O'Fallon, R T Collins, R F Morton, H H Tewfik, R L Moore, A R Frank, R E Urias, R L Deming
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 35 Issue 2 Pg. 299-303 (May 01 1996) ISSN: 0360-3016 [Print] United States
PMID8635937 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Aminosalicylic Acids
  • olsalazine
Topics
  • Aged
  • Aminosalicylic Acids
  • Contraindications
  • Defecation (drug effects)
  • Diarrhea (chemically induced, epidemiology, prevention & control)
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Incidence
  • Male
  • Pelvic Neoplasms (radiotherapy)
  • Spasm (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: